03/10/2014 - 14:10
MADRID – Combining the investigational MEK inhibitor cobimetinib with the BRAF inhibitor vemurafenib nearly halved the risk of progression in previously untreated patients with BRAF-mutated advanced...
Field of Interest: Oncology
Categories:
News Feed: Internal Medicine News - Oncology